Evidence map›Paper›PMID 27965446›Full record

ArticlemBio2016

Chlamydia trachomatis Is Resistant to Inclusion Ubiquitination and Associated Host Defense in Gamma Interferon-Primed Human Epithelial Cells.

Arun K Haldar, Anthony S Piro, Ryan Finethy, Scott T Espenschied, Hannah E Brown, Amanda M Giebel, Eva-Maria Frickel, David E Nelson, Jörn Coers

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. ThebioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. mBio · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Insights into innate immune cell evasion byFrontiers in immunology · 2024
    Review
  17. Article
  18. ATG9A supportsMicrobiology spectrum · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Arun K HaldarDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Anthony S PiroDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Ryan FinethyDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Scott T EspenschiedDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Hannah E BrownDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Amanda M GiebelDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Eva-Maria FrickelThe Francis Crick Institute, Host-Toxoplasma Interaction Laboratory, London, United Kingdom.
David E NelsonDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Jörn CoersDepartments of Molecular Genetics and Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina, USA jorn.coers@duke.edu.
Duke Medical Center · USDuke University · USIndiana University School of MedicineThe Francis Crick Institute · GB

Funding

Genetic analysis of mechanisms of chlamydial immune evasionR01AI099278 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI NELSON, DAVID EMMET · 2012 to 2023
$4.6M
IRGM-driven host responses to Chlamydia trachomatis infectionsR01AI103197 · NIAID · DUKE UNIVERSITY · PI COERS, JOERN · 2013 to 2023
$4.2M
Interferon-inducible cell-intrinsic host defense against Chlamydia trachomatisR37AI103197 · NIAID · DUKE UNIVERSITY · PI Jorn Coers · 2024 to 2026
$1.6M
Genetic analysis of mechanisms of chlamydial immune evasionR56AI099278 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI NELSON, DAVID EMMET · 2017 to 2017
$579k
Medical Research Council MC_UP_1202/12NIAID NIH HHS R01 AI099278NIAID NIH HHS R01 AI103197NIAID NIH HHS R37 AI103197NIAID NIH HHS R56 AI099278Wellcome TrustWellcome Trust 091664/B/10/Z
6 · The paper itself

Abstract

The cytokine gamma interferon (IFN-γ) induces cell-autonomous immunity to combat infections with intracellular pathogens, such as the bacterium Chlamydia trachomatis The present study demonstrates that IFN-γ-primed human cells ubiquitinate and eliminate intracellular Chlamydia-containing vacuoles, so-called inclusions. We previously described how IFN-γ-inducible immunity-related GTPases (IRGs) employ ubiquitin systems to mark inclusions for destruction in mouse cells and, furthermore, showed that the rodent pathogen Chlamydia muridarum blocks ubiquitination of its inclusions by interfering with mouse IRG function. Here, we report that ubiquitination of inclusions in human cells is independent of IRG and thus distinct from the murine pathway. We show that C. muridarum is susceptible to inclusion ubiquitination in human cells, while the closely related human pathogen C. trachomatis is resistant. C. muridarum, but not C. trachomatis, inclusions attract several markers of cell-autonomous immunity, including the ubiquitin-binding protein p62, the ubiquitin-like protein LC3, and guanylate-binding protein 1. Consequently, we find that IFN-γ priming of human epithelial cells triggers the elimination of C. muridarum, but not C. trachomatis, inclusions. This newly described defense pathway is independent of indole-2,3-dioxygenase, a known IFN-γ-inducible anti-Chlamydia resistance factor. Collectively, our observations indicate that C. trachomatis evolved mechanisms to avoid a human-specific, ubiquitin-mediated response as part of its unique adaptation to its human host. IMPORTANCE: Chlamydia trachomatis is the leading cause of sexually transmitted bacterial infections and responsible for significant morbidity, including pelvic inflammatory disease, infertility, and ectopic pregnancies in women. As an obligate intracellular pathogen, C. trachomatis is in perpetual conflict with cell-intrinsic defense programs executed by its human host. Our study defines a novel anti-Chlamydia host resistance pathway active in human epithelial cells. This defense program promotes the deposition of the small antimicrobial protein ubiquitin on vacuoles containing Chlamydia We show that this ubiquitin-based resistance pathway of human cells is highly effective against a Chlamydia species adapted to rodents but ineffective against human-adapted C. trachomatis This observation indicates that C. trachomatis evolved strategies to avoid entrapment within ubiquitin-labeled vacuoles as part of its adaptation to the human innate immune system.

Indexed as

Host-Pathogen InteractionsA549 CellsAnimalsChlamydia muridarumChlamydia trachomatisEpithelial CellsGTP-Binding ProteinsHeLa CellsHumansImmunity, InnateInclusion BodiesInterferon-gammaMiceMicrotubule-Associated ProteinsUbiquitinationVacuolesGBP1 protein, humanGTP-Binding ProteinsIFNG protein, humanInterferon-gammaMAP1LC3A protein, humanMicrotubule-Associated Proteins

Identifiers

PMID27965446
PMCPMC5156299
OpenAlexW2562529271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.